The unique design of OPTIMIZE-1, incorporating a tumor-priming dose of mitazalimab prior to chemotherapy,16 allowed us to study the correlation between CD40 stimulation and survival benefits (Figure 4A, “Tumor-priming phase—Mita effects”). The gene discussed is CD40; the disease is neoplasm.